Immunology of Cardiac Arrest and Lung Fibrosis
Brigham and Women's Hospital
Harvard Medical School
Pulmonary and Critical Care Medicine
Hale Building for Transformative Medicine
ekim11 at bwh.harvard.edu
2023-2027
-
Resolution of inflammation after cardiac arrest
-
NIH/NHLBI R01HL166487
-
PI: Kim ($2,152,844)
-
Immune checkpoints as a therapeutic target in cardiac arrest.
2020-2025
-
Deferoxamine for the prevention of acute kidney injury
-
NIH/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01DK125786
-
(PI: David Leaf)
-
RCT of iron chelation therapy in cardiothoracic surgery.
2021-2023
-
Transformational Project Award: I-CAN: A collaborative research network to discover immunological therapies for cardiac arrest
-
American Heart Association 20TPA35500016
-
PI: Kim ($272,730)
-
Discovery methods in clinical cardiac arrest.
2021-2023
-
T cell – fibroblast axes drive early, unclassified interstitial lung disease
-
American Lung Association DA-827785
-
PI: Kim ($100,000)
-
Define cellular interactions driving inflammatory unclassified lLD.
2022-2023
-
Molecular target identification in unclassifiable interstitial lung disease (ulLD)
-
Brigham and Women’s Hospital Bell Family Award
-
PI: Kim ($25,000)
-
Discovery platforms on lung tissue from patients with earlier-stage ILD.
2022-2026
-
Hepcidin-Ferroportin-Iron axis in cardiac surgery-associated acute kidney injury
-
NIH/NIDDK R01DK126685
-
(PI: David Leaf)
-
Association of hepcidin and iron regulatory pathways with acute kidney injury in patients undergoing cardiac surgery.